Treatment for non-genotype-1 HCV is a major unmet medical need in its own right, but it has been all but ignored by Wall Street amid the buzz surrounding the larger market for genotype-1.
Source of graphic: Novartis
“The efficient-market hypothesis may be the foremost piece of B.S. ever promulgated in any area of human knowledge!”